Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with Tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: Results from the ACTG A5175 PEARLS study

• Main Authors: Celum C., Hong T., Cent A., Donnell D., Morrow R., Baeten J., Firnhaber C., Grinsztejn B., Hosseinipour M., Lalloo U., Nyirenda M., Riviere C., Sanchez J., Santos B., Supparatpinyo K., Hakim J., Kumarasamy N., Campbell T.
• Format: Journal
• Published: 2017
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85019691645&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/40651
• Institution: Chiang Mai University

© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. Objective: Tenofovir disoproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro activity against herpes simplex virus type 2 (HSV-2) and reduced HSV-2 acquisition as preexposure prophylaxis. Whether TDF-containing antiretroviral therapy (ART) reduces HSV-2 acquisition is unknown. Design: Secondary analysis of AIDS Clinical Trials Group A5175, a randomized, open-label study of 3 ART regimens among 1571 participants. Methods: HSV-2 serostatus was assessed at baseline, at study exit, and before a change in ART regimen. Results: Of 365 HSV-2-seronegative persons, 68 acquired HSV-2, with 24 receiving TDF-containing ART and 44 receiving ART without TDF (HSV-2 seroconversion incidence, 6.42 and 6.63 cases/100 person-years, respectively; hazard ratio, 0.89; 95% confidence interval,.55-1.44). Conclusions: HSV-2 acquisition was not reduced in HIVinfected, HSV-2-uninfected persons during TDF-containing ART.